Compare · MCK vs MEDS
MCK vs MEDS
Side-by-side comparison of McKesson Corporation (MCK) and TRxADE HEALTH Inc. (MEDS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MCK and MEDS operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- MCK is the larger of the two at $116.43B, about 8478.5x MEDS ($13.7M).
- Over the past year, MCK is up 27.5% and MEDS is down 87.5% - MCK leads by 115.0 points.
- MEDS has been more active in the news (9 items in the past 4 weeks vs 3 for MCK).
- MCK has more recent analyst coverage (25 ratings vs 1 for MEDS).
- Company
- McKesson Corporation
- TRxADE HEALTH Inc.
- Price
- $1005.29+0.65%
- $2.67-5.15%
- Market cap
- $116.43B
- $13.7M
- 1M return
- +14.29%
- -41.96%
- 1Y return
- +27.55%
- -87.49%
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 3
- 9
- Recent ratings
- 25
- 1
McKesson Corporation
McKesson Corporation provides healthcare supply chain management, retail pharmacy, community oncology and specialty care, and healthcare information solutions in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment offers CoverMyMeds solution to help patients get the medications; RelayHealth, a workflow solution; RxCrossroads solution for therapies and interventions to biopharma manufacturers; and McKesson Prescription Automation, a customized pharmacy automation technology; and Multi-Client Central Fill as a Service, a pharmacy. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
TRxADE HEALTH Inc.
TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which fosters price transparency and serves approximately 11,800 members; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Land O' Lakes, Florida.
Latest MCK
- SEC Form 8-K filed by McKesson Corporation
- CD&R and McKesson Corporation Sign Agreement to Acquire Option Care Health
- McKesson Corporation Extends Pharmaceutical Distribution Agreement with CVS Health
- McKesson Corporation Announces Second Quarter Fiscal 2027 Earnings Release Date
- SVP, Controller & CAO Rutledge Napoleon B Jr sold $98,951 worth of shares (111 units at $891.45) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 521 units (SEC Form 4)
- McKesson Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- McKesson Signs Agreement to Acquire Precision Medicine Group, LLC
- RBC Capital Mkts initiated coverage on McKesson with a new price target
- SEC Form 4 filed by EVP and Chief Strategy Officer Srinivasan Ramesh (Nmn)
- Director Lerman Bradley E sold $268,590 worth of shares (301 units at $892.33), closing all direct ownership in the company (SEC Form 4)
Latest MEDS
- DataMeds Applauds FDA's Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health's Peptides Roadmap
- DataMEDS Si Licenses U.S. Rights To Reboot Health AI's Direct-To-Consumer GLP-1 Weight Management Platform
- DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division
- DataMEDS SI Announces Helomics Receives Medicaid Coverage Policy For Chemofx(R) Assay In Gynecologic Cancers
- Datameds AI Files DBAs Datameds SI And Corexa Health SI And Reminds Shareholders Of Record As Of August 7, 2026 Of Dream Bowl Meme Coin I Payment
- These Stocks Roar into October with Fresh Catalysts
- DataMeds AI's Corexa Pharmacy Surpasses $1 Million In Monthly Revenue
- 4 Explosive Stories Enter the Investor Spotlight
- DataMeds AI and Tollo Health Announce Launch of 'Health Lives Here' Mobile Application
- DataMEDS AI To Present At 2026 National Telehealth and Virtual Care Summit